A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet

This study has been completed.
Sponsor:
Information provided by:
Genentech
ClinicalTrials.gov Identifier:
NCT00312026
First received: April 5, 2006
Last updated: March 11, 2014
Last verified: March 2014

April 5, 2006
March 11, 2014
April 2006
Not Provided
The primary efficacy outcome measure is the proportion of patients who achieve a PGA rating of clear (0), almost clear (1), or mild (2) at Day 84.
To evaluate the efficacy of a 12 week course of 1.0 mg/kg/week of subcutaneous (SC) efalizumab compared with placebo in adults (18 years of age and older) with chronic moderate to severe plaque psoriasis involving the hands and/or feet.
Complete list of historical versions of study NCT00312026 on ClinicalTrials.gov Archive Site
  • The proportion of patients who achieve a PGA rating of clear (0), almost clear (1), or mild (2) at Day 42
  • The proportion of patients who achieve a PGA rating of clear (0) or almost clear (1) at Day 84
  • The change from Day 0 to Day 84 in the following PRO measures: SF 36, PDS, Work Loss Questionnaire
  • The change from Day 0 in PGA rating (i.e., the number of categories changed) at Day 84
Not Provided
Not Provided
Not Provided
 
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet
A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis Involving the Hands and/or Feet

This is a Phase IV randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SC efalizumab in adult patients (18 years of age and older) with chronic moderate to severe plaque psoriasis involving the hands and/or feet who have had no previous exposure to efalizumab. The study will consist of a screening period, a treatment period, and an observation period.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Psoriasis
Drug: efalizumab
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
75
November 2006
Not Provided

Inclusion Criteria:

  • Provide written informed consent and Health Insurance Portability and Accountability Act of 1996 (HIPAA) documents
  • Be aged 18 years or older
  • Have chronic (6 months or greater) moderate to severe plaque psoriasis involving the hands and/or feet with or without pustules and with or without psoriasis at other sites
  • Have a PGA rating of moderate (3) or severe (4) for hand and/or foot psoriasis
  • Be a candidate for systemic therapy in the opinion of the investigator
  • Be naive to efalizumab treatment
  • Weigh no more than 125 kg
  • For women of childbearing potential, use a method of contraception acceptable to the investigator to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study and for 6 weeks after the last dose of efalizumab

Exclusion Criteria:

  • Have a history of hypersensitivity to efalizumab or any of its components
  • Are using any excluded therapy
  • Have a history of or ongoing alcohol or illegal drug abuse
  • Have a history of or an ongoing uncontrolled serious bacterial, viral, fungal, or atypical mycobacterial infection. This includes diagnoses that required more than 2 weeks of therapy, such as endocarditis and osteomyelitis, that have been treated in the past 6 months. In addition, if the patient is currently receiving antibiotics, antivirals, or antifungals for an infection or for suppression or prophylaxis for any diagnosis, the patient will be excluded.
  • Have any history of opportunistic infections (e.g., systemic fungal infections, parasites)
  • Are seropositive for hepatitis B antigen, hepatitis C antibody, or human immunodeficiency virus (HIV). Patients will undergo testing during screening, and any patients who are seropositive for hepatitis B antigen, hepatitis C antibody, or HIV will be excluded.
  • Have a history of active tuberculosis or are currently undergoing treatment for tuberculosis. A purified protein derivative (PPD) test or chest x-ray will be performed at the screening visit. Patients with a positive PPD test (not due to BCG vaccination) or chest x-ray will be excluded.
  • Have the presence or history of malignancy within the past 5 years, including lymphoproliferative disorders. Patients with a history of fully resolved basal or squamous cell skin cancer may be enrolled.
  • Are pregnant or lactating women
  • Have a diagnosis of hepatic cirrhosis, regardless of cause or severity
  • Have a history of thrombocytopenia
  • Have a history of hemolytic anemia
  • Have a history of clinically significant anemia
  • Have a WBC count <4,000 cells/uL or >14,000 cells/uL
  • Have a hematocrit (HCT) <30% or a hemoglobin (Hgb) level <11 g/dL
  • Have a platelet count <150,000 cells/uL
  • Have hepatic enzyme levels ≥3 times the upper limit of normal
  • Have a serum creatinine level ≥2 times the upper limit of normal
  • Have been exposed to any experimental drugs or treatments within 30 days or 5 half-lives, whichever is longer, prior to the screening visit
  • Have had any previous exposure to efalizumab
  • Have been vaccinated with a live virus or live bacteria within the 14 days prior to the first dose of efalizumab
  • Have any medical condition that, in the judgment of the investigator, would jeopardize the patient's safety following exposure to study drug (efalizumab or placebo equivalent) or would significantly interfere with the patient's ability to comply with the provisions of this protocol
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00312026
ACD3753g
Not Provided
Not Provided
Genentech
Not Provided
Study Director: Ivor Caro, M.D. Genentech
Genentech
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP